134 related articles for article (PubMed ID: 16193089)
1. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.
Schützinger C; Gaiger A; Thalhammer R; Vesely M; Fritsche-Polanz R; Schwarzinger I; Ohler L; Simonitsch-Klupp I; Reinhard F; Jäger U
Leukemia; 2005 Nov; 19(11):2005-8. PubMed ID: 16193089
[No Abstract] [Full Text] [Related]
2. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
Au WY; Lam CC; Chim CS; Pang AW; Kwong YL
Leuk Res; 2005 Oct; 29(10):1213-5. PubMed ID: 16111536
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
Ru X; Liebman HA
Br J Haematol; 2003 Oct; 123(2):278-81. PubMed ID: 14531909
[TBL] [Abstract][Full Text] [Related]
4. [Pathophysiology and treatment of large granular lymphocyte leukemia-associated pure red cell aplasia].
Fujishima N
Rinsho Ketsueki; 2010 Aug; 51(8):589-96. PubMed ID: 20805663
[No Abstract] [Full Text] [Related]
5. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
Thachil J; Salim R
Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
[No Abstract] [Full Text] [Related]
6. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
7. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
Monjanel H; Hourioux C; Arbion F; Colombat P; Lissandre S; Regner MP; Senecal D
Leuk Res; 2010 Aug; 34(8):e197-9. PubMed ID: 20211489
[No Abstract] [Full Text] [Related]
8. Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab.
Pham DC; Guthrie TH; Villas BH; Salazar E
Am J Hematol; 2008 Jul; 83(7):603. PubMed ID: 18273896
[No Abstract] [Full Text] [Related]
9. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia.
Olteanu H; Harrington AM; Ramirez S; Kroft SH; Hari P
Br J Haematol; 2010 Aug; 150(4):480-1. PubMed ID: 20456357
[No Abstract] [Full Text] [Related]
11. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
Aribi A; Huh Y; Keating M; O'brien S; Ferrajoli A; Faderl S; Wierda W; Kantarjian H; Ravandi F
Leuk Res; 2007 Jul; 31(7):939-45. PubMed ID: 17045649
[TBL] [Abstract][Full Text] [Related]
12. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
Rosenblum MD; LaBelle JL; Chang CC; Margolis DA; Schauer DW; Vesole DH
Blood; 2004 Mar; 103(5):1969-71. PubMed ID: 14976065
[No Abstract] [Full Text] [Related]
14. [T-cell large granular lymphocytic leukemia associated with pure red cell aplasia, successfully treated with cyclophosphamide].
Mátrai Z; Lelkes G; Milosevits J; Páldiné HP; Pecze K
Orv Hetil; 1997 Aug; 138(33):2075-80. PubMed ID: 9304100
[TBL] [Abstract][Full Text] [Related]
15. Red cell aplasia due to parvovirus b19 in a patient treated with alemtuzumab.
Crowley B; Woodcock B
Br J Haematol; 2002 Oct; 119(1):279-80. PubMed ID: 12358942
[No Abstract] [Full Text] [Related]
16. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
[No Abstract] [Full Text] [Related]
17. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
Chaar BT; Petruska PJ
Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
[No Abstract] [Full Text] [Related]
18. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.
Rodon P; Breton P; Courouble G
Eur J Haematol; 2003 May; 70(5):319-21. PubMed ID: 12694169
[TBL] [Abstract][Full Text] [Related]
19. Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia.
Sasaki M; Sugimoto K; Kawahara S; Yasuda H; Suto H; Oshimi K
Eur J Haematol; 2007 Jun; 78(6):545. PubMed ID: 17419749
[No Abstract] [Full Text] [Related]
20. Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia.
Chow JK; Chan TK
Hong Kong Med J; 2013 Dec; 19(6):549-52. PubMed ID: 24310664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
